Onyx Shares Zoom on Cancer-Drug News

The company and partner Bayer ended trials of Nexavar early after data showed the drug's efficacy in treating liver cancer

Bayer Pharmaceuticals (BAY) and Onyx Pharmaceuticals (ONXX) had seen enough. Based on trial data, their new drug Nexavar actually helps people with liver cancer survive longer. The companies said Feb. 12 that they're planning to end their advanced stage trials of the drug early, after their study already showed Nexavar's efficacy. Now other patients in the study who had received placebos instead of the drug can have access to Nexavar too.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.